Clinical Trial Update: Dose Response Study of Patients With Erythematous Rosacea [Phase 2]

View source ↗

Summary

This Phase 2 dose-response trial evaluating a treatment for erythematous rosacea (Type One) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rosacea

Snippet

Sponsor: Vicept Therapeutics, Inc. | Conditions: Erythematous (Type One) Rosacea | Phase 2 | Status: COMPLETED